$ICCC

Biotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.

ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q2 2026. Total product sales were $7.2 million, up 11.5% year over year, with domestic sales up 27.7% and international down 38.9%. For the first six months, sales rose 20.9% to $17.5 million. Management will discuss results on Aug. 14, 2026.

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. iccc20260708_8k.htm false 0000811641 0000811641 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

te Boekhorst Paul Francis Olivier (President and CEO) purchased 8,000 shares of IMMUCELL CORP /DE/ (ICCC) at $9.50 on 2026-06-18.

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. iccc20260615_8k.htm false 0000811641 0000811641 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

ImmuCell Corporation (NASDAQ:ICCC) has announced new employment agreements and stock option grants for CFO Timothy C. Fiori and SVP of Sales and Marketing Bobbi Jo Brockmann, effective January 27. The agreements include base salaries, performance-based annual cash bonuses, and stock options vesting over three years. Additionally, CEO Olivier te Boekhorst received a performance-based stock option grant contingent on significant net operating income growth for fiscal year 2025.

SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.

PORTLAND, Maine, Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- ImmuCell Corporation ( Nasdaq: ICCC ) ( "ImmuCell" or the "Company" ) , a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and ...

ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.

ImmuCell ( NASDAQ:ICCC ) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million. Strategic updates included the completion of First Defense production capacity expansion and ongoing ...